🔰Lean type 2 diabetes: the overlooked epidemic reshaping global health. 🤓How fascinating is everything surrounding T2DM Lean T2DM represents an underrecognized epidemic requiring fundamental transformation from weight-centric models toward precision medicine frameworks that

📌Management of Peripheral Artery Disease in Adults With #Diabetes: 2025 @ACCinTouch Scientific Statement📝 #Positionpaper #PAD #T2DM

Modulating the Gut Microbiome in Type 2 Diabetes: Nutritional & Therapeutic Strategies ▶️Nutritional modulation of the gut microbiota is a promising adjunctive therapy for the improvement of glycemic control in T2DM. ▶️While probiotics, prebiotics, synbiotics, & food bioactive

🫃#Obesity drives CKD🫘 mostly indirectly (56–83%) via HTN, T2DM & atherosclerosis. 💉GLP-1 RAs hit every mediator: massive weight loss 📉+ BP/glucose control 📏+ direct kidney/cardio protection🫀 Game-changing for obese CKD patients ± DM https://t.co/K7viCjNl0q #CKD #GLP1

Yerba mate shows promise for blood sugar and cholesterol control. In a 60-day RCT, Yerba Mate for T2DM and prediabetes led to: • HbA1c ↓ by 0.85% • Fasting glucose ↓ by 25 mg/dL • LDL ↓ Everyone is talking about GLP-1. But what most people don't realize is that our

🍔#Obesity = a chronic inflammatory disease of dysfunctional visceral adipose tissue. 🧬Genetic, environmental🌴, and behavioral drivers → inflammation 🔥→ T2DM, CAD, CKD, MASLD, HF An evolving paradigm in cardiometabolic care 🔗 https://t.co/sVc42XxZMN 🆕 #NephX

🔁 Throwback Thursday: Diabetes Trial Files Edition 📌 Intensive glycemic control 📌 Captopril for diabetic nephropathy 📌 CABG/PCI vs. medical therapy in T2DM + CAD 🧵 Read more: https://t.co/1aiUwjXzXM #Diabetes #Cardiology #Nephrology #FOAMed

#POCUS Case of the Week - Kicking off 2026! 50 yo male w/ PMH of HTN, recurrent kidney stones, T2DM. Presents w/ bilateral flank/back pain x 5 days. Afebrile, VS stable. UA: microscopic hematuria, no signs of infection. POCUS left kidney (sagittal view) below. What do you

Effectiveness & Safety of Statins in Type 2 Diabetes Across Baseline CV Risk (Annals of Internal Medicine, Dec 30, 2025) 🧠 Core Concept Diabetes itself is a cardiovascular risk amplifier — statins confer benefit even in “low-risk” T2DM, challenging the traditional

Case alert 🚨 72-y man, T2DM on metformin 8 yrs + daily PPI >2 yrs, presents with numb feet, gait imbalance, exertional dyspnea. Hb 10.2 g/dL, MCV 112 fL, B12 140 pg/mL, ↑MMA & homocysteine. Anemia absent earlier what’s the link?

🧬 Diabetes Trial Files – New Issue 💉 Tirzepatide + basal insulin: ~2.4% HbA1c ↓ 🤰 Empa in GDM: No β-cell benefit 🧪 Mifepristone: ↓ HbA1c in T2DM + hypercortisolism, but high AE dropouts 📖 https://t.co/9CSdEGNg1t #FOAMed #Diabetes #T2DM #Endocrinology #MedTwitter

❓Is #Anxiety hiding early #Dementia cases?🤯Misdiagnosis delays help!⏳ #T2DM = longer diagnosis time! @Biomed_MDPI @MDPIOpenAccess #MentalHealthMatters #NeuroScience #EarlyDiagnosis 🧪 Dive deeper 📚 https://t.co/uhL6gZc5SF

Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta-analysis SGLT2 inhibitors followed by GLP-1 RA provide strong benefits for CV and kidney health in patients with T2DM and

Preventing diabetes : Type 2 diabetes mellitus (T2DM) is a condition in which there is too much glucose circulating in the blood because of long-standing increases in insulin resistance leading to the eventual deficiency in insulin responsiveness to hyperglycaemia [51,52].

🧠People with #T2DM face ↑ risk of cognitive decline. ✨ Systematic review of 18 RCTs 💡 Early & sustained GLP-1RA therapy may protect the brain! https://t.co/wMvrOvgkdc

Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients New-onset UTI was associated with an increased risk of cardiovascular and renal events in patients with T2DM prescribed SGLT2 inhibitors. Discontinuing SGLT2 inhibitors

❗️A bit delayed but results from SURPASS CVOT out now❗️ 🔹Comparison Tirzepatide vs Dulaglutide in T2DM 🔸Non-inferiority met according to pre-specified CI limits 🔹Superiority not shown 🔸Good weight loss and Hba1c lowering in both arms 🔹SURPASS MMO will be interesting in

今日も駅のビアードパパでパイシューです🤤

Youth-onset T2DM needs adult-level potency early—and SURPASS-PEDS shows tirzepatide delivers exactly that. SURPASS-PEDS Trial | Tirzepatide in Youth-Onset Type 2 Diabetes Unmet need: Youth-onset T2DM is more aggressive, less responsive to metformin/insulin, and associated with